Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Resistance Mechanisms
100%
Enhancer of Zeste Homolog 2 (EZH2)
100%
Enhancer of Zeste Homolog 2 Inhibitors
100%
Diffuse Large B-cell Lymphoma Cells
33%
Growth Factors
22%
A1 Receptor
22%
Insulin-like
22%
Inhibitor Resistant
22%
Phosphoinositide 3-kinase Pathway
22%
GSK126
22%
Antitumor Effect
11%
Drug Resistance
11%
Mitogen-activated Protein Kinase
11%
Constitutive Activation
11%
Targeted Therapy
11%
Phosphoinositide 3-kinase (PI3K)
11%
Lymphoma Cells
11%
Proteinase Inhibitor
11%
AKT Pathway
11%
Common Mechanisms
11%
Targeted Therapeutics
11%
Lessons Learned
11%
Forkhead Box O3 (FOXO3)
11%
Unified Approach
11%
Resistance to Targeted Therapy
11%
TNFSF10
11%
UNC1999
11%
Inhibitor Binding
11%
Acquired mutations
11%
Cellular Thermal Shift Assay (CETSA)
11%
Embryonic Ectoderm Development
11%
Medicine and Dentistry
Lymphoma Cell
100%
Transcription Factor EZH2
100%
Diffuse Large B-Cell Lymphoma
41%
Phosphoinositide 3-Kinase
25%
Targeted Therapy
16%
Somatomedin C Receptor
16%
B Cell Lymphoma Cell
16%
Mitogen-Activated Protein Kinase
8%
Drug Resistance
8%
Protein Inhibitor
8%
Targeted Therapeutic Agent
8%
Diffuse Large B-Cell Lymphoma Cell Line
8%
Embryonic Ectoderm Development Protein
8%
Pharmacology, Toxicology and Pharmaceutical Science
Transcription Factor EZH2
100%
Diffuse Large B Cell Lymphoma
50%
Phosphatidylinositol 3 Kinase
25%
Somatomedin C Receptor
16%
Drug Resistance
8%
Protein Inhibitor
8%
Embryonic Ectoderm Development Protein
8%
Biochemistry, Genetics and Molecular Biology
Transcription Factor EZH2
100%
B Cell
41%
Phosphoinositide 3-Kinase
25%
Insulin-Like Growth Factor 1 Receptor
16%
Drug Resistance
8%
Mitogen-Activated Protein Kinase
8%
FOXO3
8%
Embryonic Ectoderm Development Protein
8%